Deep-dive company profiles, commercial trajectory, pipeline catalysts, and positioning frameworks for covered names.
Quiet quarter but real tells in the margins. Uptick in reimbursement approvals, early ex-US traction, aesthetic delay is capital discipline, and the CF FDA alignment meeting is the near-term hinge catalyst. At ~280 bps, this is a "monitor, don't force" situation—no thesis change, no new red flag, just watching entry levels.
At ~280 bps you're debating whether to lean into a name where commercial execution is tracking, pipeline probability is perceived as high, and a near-term catalyst exists—but valuation embeds both commercial durability and CF upside. Connor and Jeremy framing 270 as reasonable tells you they're anchoring to a technical add zone rather than reacting to the quarter. No thesis change, no new red flag, just watching entry levels.
FDA effectively reset prior guidance on Huntington's Disease gene therapy, requiring additional study. Commissioner Makary's public comments consistent with this posture. PM pathway unlikely to provide a shortcut for programs where FDA believes efficacy isn't established. Regulatory overhang persists.
| Program | Stage | Regulatory Status | Key Risk |
|---|---|---|---|
| AMT-130 (Huntington's Disease) | Phase I/II | Guidance Reset | FDA wants additional study; prior guidance no longer bankable |
Exposed to the same gene-therapy regulatory re-tightening that hit QURE. Center leadership churn creates structural unpredictability for any program relying on prior FDA guidance alignment. PM pathway scope for platform gene therapies remains unclear.
| Program | Stage | Regulatory Status | Key Risk |
|---|---|---|---|
| AAV Gene Therapy Platform | Multiple programs | Monitoring | Read-through from QURE/HD reset; center leadership churn |
COMP006 Phase 3 hit primary in TRD (MADRS -3.8, p<0.001). Durability demonstrated through Week 26. FDA meeting requested for rolling NDA; submission target Q4 2026. Clean "approval probability repricing" event.
| Program | Stage | Status | Next Catalyst |
|---|---|---|---|
| COMP360 (Psilocybin) — TRD | Phase 3 (COMP006) | Primary Met | FDA pre-NDA meeting; NDA Q4 2026 |
| Ticker | Company | Lead Program | Stage | Status | Next Catalyst |
|---|---|---|---|---|---|
| KRYS | Krystal Biotech | Baijuvek (DEB) / CF | Commercial / Pre-Ph3 | On Track | CF FDA alignment 1H 2026 |
| QURE | uniQure | AMT-130 (Huntington's) | Phase I/II | Guidance Reset | Study design TBD |
| RGNX | REGENXBIO | AAV Platform | Multiple | Watch | Read-through monitoring |
| CMPS | Compass Pathways | COMP360 (TRD) | Phase 3 Complete | NDA Track | FDA meeting; NDA Q4 2026 |
| OCUL | Ocular Therapeutix | AXPAXLI (wet AMD) | Phase 3 Complete | Mixed Read | Macula Society Feb 25–28 |
| IRON | Disc Medicine | Bitopertin | Late-stage | Path Clear | Data Q4 2026; FDA ~mid-2027 |
| HELP | Helus Pharma | HLP004 (GAD) | Phase 2 | Data Pending | Topline Q1 2026 |
| PLYX | Polaryx Therapeutics | PLX-200 (SOTERIA) | Phase 2 initiating | Operational | Trial initiation 1H 2026 |